Bromuro de Ipratropio

Bromuro de Ipratropio may be available in the countries listed below.

Ingredient matches for Bromuro de Ipratropio

Ipratropium

Ipratropium Bromide is reported as an ingredient of Bromuro de Ipratropio in the following countries:

• Peru

International Drug Name Search

Aldazide

Aldazide may be available in the countries listed below.

Ingredient matches for Aldazide

Butizide

Butizide is reported as an ingredient of Aldazide in the following countries:

• Indonesia


• South Africa

Spironolactone

Spironolactone is reported as an ingredient of Aldazide in the following countries:

• Indonesia


• South Africa

International Drug Name Search

Dexol 5

Dexol 5 may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Dexol 5

Dexamethasone

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Dexol 5 in the following countries:

• Australia


• New Zealand

International Drug Name Search

Nervex

Nervex may be available in the countries listed below.

Ingredient matches for Nervex

Mecobalamin

Mecobalamin is reported as an ingredient of Nervex in the following countries:

• Bangladesh

International Drug Name Search

Quinalar

Quinalar may be available in the countries listed below.

Ingredient matches for Quinalar

Quinapril

Quinapril hydrochloride (a derivative of Quinapril) is reported as an ingredient of Quinalar in the following countries:

• Venezuela

International Drug Name Search

Rosoxacin

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

J01MB01

CAS registry number (Chemical Abstracts Service)

0040034-42-2

Chemical Formula

C17-H14-N2-O3

Molecular Weight

294

Therapeutic Category

Antiinfective, quinolin-derivative

Chemical Name

3-Quinolinecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-

Foreign Names

• Rosoxacinum (Latin)
• Rosoxacin (German)
• Rosoxacine (French)
• Rosoxacino (Spanish)

Generic Names

• Acrosoxacin (OS: BAN)
• Rosoxacin (OS: USAN, BAN)
• Rosoxacine (OS: DCF)
• TO 133 (IS)
• Win 35213 (IS)

Brand Names

• Eradacil
  Sanofi-Aventis, Bahrain; Sanofi-Aventis, Brazil; Sanofi-Aventis, Egypt; Sanofi-Aventis, Kuwait; Sanofi-Aventis, Lebanon; Sanofi-Aventis, Qatar; Sanofi-Aventis, Saudi Arabia; Sanofi-Synthelabo, United Arab Emirates; Sanofi-Synthelabo, Cyprus; Sanofi-Synthelabo, Jordan

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Proinsul

Proinsul may be available in the countries listed below.

Ingredient matches for Proinsul

Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Proinsul in the following countries:

• Dominican Republic

International Drug Name Search

Diurace

DiurAce may be available in the countries listed below.

Ingredient matches for DiurAce

Fosinopril

Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of DiurAce in the following countries:

• Netherlands

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of DiurAce in the following countries:

• Netherlands


• Peru

International Drug Name Search

Burana-C

Burana-C may be available in the countries listed below.

Ingredient matches for Burana-C

Ascorbic Acid

Ascorbic Acid is reported as an ingredient of Burana-C in the following countries:

• Finland

Ibuprofen

Ibuprofen is reported as an ingredient of Burana-C in the following countries:

• Finland

International Drug Name Search

Skelaxin

Skelaxin is a brand name of metaxalone, approved by the FDA in the following formulation(s):

SKELAXIN (metaxalone - tablet; oral)

• 
  Manufacturer: KING PHARMS
  
  Approval date: August 30, 2002
  
  Strength(s): 800MG ^[RLD][AB]

Has a generic version of Skelaxin been approved?

A generic version of Skelaxin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Skelaxin and have been approved by the FDA:

metaxalone tablet; oral

• 
  Manufacturer: SANDOZ
  
  Approval date: March 31, 2010
  
  Strength(s): 800MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Skelaxin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for increasing the bioavailability of metaxalone
  Patent 6,407,128
  Issued: June 18, 2002
  Inventor(s): Michael; Scaife & Jaymin; Shah
  Assignee(s): Elan Pharmaceuticals, Inc.
  A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
  
  



• 
  Methods of using metaxalone in the treatment of musculoskeletal conditions
  Patent 6,683,102
  Issued: January 27, 2004
  Inventor(s): Michael; Scaife & Jaymin; Shah
  Assignee(s): Elan Pharmaceuticals, Inc.
  A method of increasing the bioavailability of metaxalone by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
  
  



• 
  Metaxalone products, method of manufacture, and method of use
  Patent 7,122,566
  Issued: October 17, 2006
  Inventor(s): Du; Jie & Roberts; Richard H.
  Assignee(s): Mutual Pharmaceutical Company, Inc.
  Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
  
  Patent expiration dates:
  
  
  • February 6, 2026
    
    ✓ 
    Patent use: TREATMENT OF MUSCULOSKELETAL CONDITIONS
  
  



• 
  Methods of modifying the bioavailability of metaxalone
  Patent 7,714,006
  Issued: May 11, 2010
  Inventor(s): Scaife; Michael C. & Davis; Charles C.
  Assignee(s): King Pharmaceuticals Research & Development, Inc.
  A method of increasing the bioavailability, and decreasing the effect of age on the bioavailability, of metaxalone, by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of metaxalone in a suitable container and associated with printed labeling which describes the increased bioavailability, and decreased effect of age on bioavailability, of the medication in the container, when taken with food.
  
  Patent expiration dates:
  
  
  • December 3, 2021
    
    ✓ 
    Patent use: USE OF METAXALONE FOR TREATMENT OF MUSCULSKELETAL CONDITIONS
  
  

See also...

• Skelaxin Consumer Information (Drugs.com)
• Skelaxin Consumer Information (Wolters Kluwer)
• Skelaxin Consumer Information (Cerner Multum)
• Skelaxin Advanced Consumer Information (Micromedex)
• Skelaxin AHFS DI Monographs (ASHP)
• Metaxalone Consumer Information (Wolters Kluwer)
• Metaxalone Consumer Information (Cerner Multum)
• Metaxalone Advanced Consumer Information (Micromedex)
• Metaxalone AHFS DI Monographs (ASHP)

Plenaer

Plenaer may be available in the countries listed below.

Ingredient matches for Plenaer

Flunisolide

Flunisolide is reported as an ingredient of Plenaer in the following countries:

• Italy

Salbutamol

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Plenaer in the following countries:

• Italy

International Drug Name Search

Lumex

Lumex may be available in the countries listed below.

Ingredient matches for Lumex

Lomefloxacin

Lomefloxacin hydrochloride (a derivative of Lomefloxacin) is reported as an ingredient of Lumex in the following countries:

• Bangladesh

International Drug Name Search

Dopamine Aguettant

Dopamine Aguettant may be available in the countries listed below.

Ingredient matches for Dopamine Aguettant

Dopamine

Dopamine is reported as an ingredient of Dopamine Aguettant in the following countries:

• Tunisia

Dopamine hydrochloride (a derivative of Dopamine) is reported as an ingredient of Dopamine Aguettant in the following countries:

• France

International Drug Name Search